Ocumension Therapeutics (HKG:1477) reported 132.3 million yuan in loss for the first half of 2025, narrowing from a loss of 151.3 million yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.

Loss per share was 0.17 yuan, compared with 0.23 yuan in the prior year.

Revenue at the drug company increased 75% year-on-year to 294 million yuan, figures showed.

Meanwhile, in a separate announcement, the company said its OT-301 drug candidate met the main goal of a second late-stage study.

The drug was found to be non-inferior to the current standard of care latanoprost in the phase 3 Denali trial of subjects with an eye condition called pen-angle glaucoma or ocular hypertension.

As a result, the medicine now meets the requirements for new drug approval in China, the firm said.

Ocumension Therapeutics is developing OT-301, also known as NCX 470, with Nicox.